Comparative monitoring of oral theophylline treatment in blood serum, saliva, and nasal mucus

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 217-221

  Henkin, Robert I ^a  

^a Taste and Smell Clinic   (United States)

Author keywords

blood; hyposmia; nasal mucus; saliva; theophylline treatment

Indexed keywords

THEOPHYLLINE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG NASAL MUCUS LEVEL; DRUG SALIVA LEVEL; FEMALE; HUMAN; HYPOSMIA; MALE; NON INVASIVE PROCEDURE; NOSE MUCUS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; OLFACTION DISORDERS; PHOSPHODIESTERASE INHIBITORS; SALIVA; THEOPHYLLINE; TISSUE DISTRIBUTION; UNITED STATES;

EID: 84858697832     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182492a20     Document Type: Article

References (78)

1. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 1991;46:512-523.
2. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J. 1994;7:579-591. (Pubitemid 24099019)
3. McKay SE, Howie CA, Thomson AH, et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax. 1993;48:227-232. (Pubitemid 23090241)
4. Henkin RI. Evaluation and treatment of human olfactory dysfunction. In: English GM, ed. Otolaryngology. Philadelphia, PA: Lippincott; 1993:1-86.
5. Levine JH, Michael JR, Guarnieri T. Multifocal atrial tachycardia: a toxic effect of theophylline. Lancet. 1985;1:12-14. (Pubitemid 15160542)
6. Skinner MH. Adverse reactions and interactions with theophylline. Drug Saf. 1990;5:275-285. (Pubitemid 20294971)
7. Sessler CN, Glauser FL, Cooper KR. Treatment of theophylline toxicity with oral activated charcoal. Chest. 1985;87:325-329. (Pubitemid 15139959)
8. Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med. 1988;17:134-144.
9. Gorodischer R, Burtin P, Hwang P, et al. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;16:437-443. (Pubitemid 24296733)
10. Levy G, Ellis EF, Koysooko R. Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva. Pediatrics. 1974;53:873-876.
11. Eney RD, Goldstein EO. Compliance of chronic asthmatics with oral administration of theophylline as measured by serum and salivary levels. Pediatrics. 1976;57:513-517.
12. Galant SP, Gillman SA, Cummins LH, et al. Reliability of salivary theophylline as a guide to plasma theophylline levels. Am J Dis Child. 1977;131:970-972.
13. Boobis S, Trembath PW, Chambers RE, et al. Salivary theophylline estimations: are they valid substitutes for plasma levels? Ther Drug Monit. 1979;1:485-494.
14. Siegel IA, Ben-Aryeh H, Gozal D, et al. Comparison of unbound and total serum theophylline concentrations with those of stimulated and unstimulated saliva in asthmatic children. Ther Drug Monit. 1990;12:460-464. (Pubitemid 20314039)
15. Lena SM, Hutchins P,Wood CB, et al. Salivary theophylline estimation in the management of asthma in children. Postgrad Med J. 1980;56:85-87. (Pubitemid 10179972)
16. Rylance GW, Beswick DT, Cullen RE, et al. Re-evaluation of saliva for monitoring theophylline concentrations. Arch Dis Child. 1985;60:66-68. (Pubitemid 15114283)
17. Goldsworthy SJ, Kemp M, Warner JO. Salivary and urine theophylline levels in management of childhood asthma. J R SocMed. 1981;74:415-418. (Pubitemid 11089364)
18. Mally J, Keszei C, Cserep G. Theophylline concentrations in serum, saliva, and cerebrospinal fluid in patients with essential tremor. Ther Drug Monit. 1992;14:135-137.
19. Blanchard J, Harvey S, Morgan WJ. Relationship between serum and saliva theophylline levels in patients with cystic fibrosis. Ther Drug Monit. 1992;14:48-54.
20. Jonkman JH, Koëter GH, Schoenmaker R, et al. Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation. Eur J Clin Pharmacol. 1981;20:73-78. (Pubitemid 11072745)
21. Henkin RI, Velicu I, Schmidt L. An open label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci. 2009;337:396-406.
22. Jolley ME, Stroupe SD, Schwenzer KS, et al. Fluorescence polarization immunoassay. iii. an automated system for therapeutic drug determination. Clin Chem. 1981;27:1575-1579. (Pubitemid 11013471)
23. Henkin RI, Lippoldt RE, Bilstad J, et al. A zinc protein isolated from human parotid saliva. Proc Natl Acad Sci USA. 1975;72:488-492.
24. Henkin RI, Velicu I, Schmidt L. Relative resistance to oral theophylline treatment in patients with hyposmia manifested by decreased secretion of nasal mucus cyclic nucleotides. Am J Med Sci. 2011;341:17-22.
25. Henkin RI, Gouliouk V, Schultz M, et al. Intranasal theophylline: A novel method to treat patients with smell loss (hyposmia). FASEB J. 2010;24: 100215.
26. Henkin RI. Report on a survey on smell in the US. Olfactory Rev. 1987;1:1-8.
27. Henkin RI, Velicu I, Papathanassiu A. cAMP and cGMP in human parotid saliva: relationships to taste and smell dysfunction, gender and age. Am J Med Sci. 2007;334:431-440. (Pubitemid 350306462)
28. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus: relationships to taste and smell dysfunction, gender and age. Clin Invest Med. 2008;31: E71-E77.
29. Kurihara K, Koyama N. High activity of adenyl cyclase in olfactory and gustatory organs. Biochem Biophys Res Commun. 1972;48:30-34.
30. Henkin RI, Velicu I. Decreased parotid salivary cyclic nucleotides related to smell loss severity in patients with taste and smell dysfunction. Metabolism. 2009;58:1717-1723.
31. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus related to severity of smell loss in patients with smell dysfunction. Clin Invest Med. 2008;31: E78-E84.
32. Escada PA, Lima C, da Silva JM. The human olfactory mucosa. Eur Arch Otorhinolaryngol. 2009;266:1675-1680.
33. Velicu I, Henkin RI. On the apoptotic mechanism of action of theophylline in restoring smell function in patients with hyposmia. J Invest Med. 2005; 53(suppl 2):S402.
34. Levy LM, Henkin RI, Hutter A, et al. Increased brain activation in response to odors in patients with hyposmia after theophylline treatment demonstrated by fMRI. J Comput Assist Tomogr. 1998;22:760-770. (Pubitemid 28457740)
35. Gudziol V, Hummel T. Effects of pentoxifylline on olfactory sensitivity: A postmarketing surveillance study. Arch Otolaryngol Head Neck Surg. 2009;135:291-295.
36. Dinter H, Onuffer J, Faulds D, et al. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J Mol Med. 1997;75:95-102. (Pubitemid 27119489)
37. Rieckmann P, Weber F, Günther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996;64:193-200. (Pubitemid 26096431)
38. Weber F, Polak T, Günther A, et al. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol. 1998;44: 27-34. (Pubitemid 28323652)
39. Sommer N, Löschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1995;1:244-248.
40. Genain CP, Roberts T, Davis RL, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA. 1995;92:3601-3605.
41. Casacchia M, Meco G, Castellana F, et al. Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease. Pharmacol Res Commun. 1983;15:329-334. (Pubitemid 13122657)
42. Weishaar RE, Cain MH, Bristol JA. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985;28:537-545. (Pubitemid 15098154)
43. Chen RW, Williams AJ, Liao Z, et al. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and Caspase-3 activation. Neurosci Lett. 2007;418:165-169. (Pubitemid 46636000)
44. Hebb AL, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol. 2007;7:86-92. (Pubitemid 46242039)
45. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129:1659-1673. (Pubitemid 43999401)
46. Wermuth CG. Multitargeted drugs: The end of the "one-target- onedisease" philosophy? Drug Discov Today. 2004;9:826-827. (Pubitemid 39286093)
47. Teixeira MM, Gristwood RW, Cooper N, et al. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci. 1997;18:164-171.
48. Blokland A, Schrieber R, Prickaerts J. Improving memory: a role for phosphodiesterases. Curr Pharm Des. 2006;12:2511-2523.
49. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006;314:781-784. (Pubitemid 44706637)
50. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2006;147(suppl 1):S252-S257. (Pubitemid 43077283)
51. Rose GM, Hopper A, De Vivo M, et al. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des. 2005;11:3329-3334. (Pubitemid 41300762)
52. Comery TA, Martone RL, Aschmies S, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25:8898-8902. (Pubitemid 41384457)
53. Zivadinov R, Zorzon M, Monti Bragadin L, et al. Olfactory loss in multiple sclerosis. J Neurol Sci. 1999;168:127-130. (Pubitemid 29467430)
54. Doty RL, Li C, Mannon LJ, et al. Olfactory dysfunction in multiple sclerosis. Relation to plaque load in inferior frontal and temporal lobes. Ann N Y Acad Sci. 1998;855:781-786. (Pubitemid 29110070)
55. Doty RL, Li C, Mannon LJ, et al. Olfactory dysfunction in multiple sclerosis. N Engl J Med. 1997;336:1918-1919.
56. Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992;55:138-142.
57. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? QJM. 1999;92:473-480. (Pubitemid 29385293)
58. Mü ller A, Reichmann H, Livermore A, et al. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm. 2002;109:805-811.
59. Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry. 2000;157:1399-1405.
60. Nordin S, Monsch AU, Murphy C. Unawareness of smell loss in normal aging and Alzheimer's disease: discrepancy between self-reported and diagnosed smell sensitivity. J Gerontol B Psychol Sci Soc Sci. 1995;50: P187-P192.
61. Murphy C, Jernigan TL, Fennema-Notestine C. Left hippocampal volume loss in Alzheimer's disease is reflected in performance on odor identification: a structural MRI study. J Int Neuropsychol Soc. 2003;9:459-471. (Pubitemid 36367334)
62. Kraft M, Torvik JA, Trudeau JB, et al. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol. 1996; 97:1242-1246. (Pubitemid 26192273)
63. Naclerio RM, Bartenfelder D, Proud D, et al. Theophylline reduces the response to nasal challenge with antigen. Am J Med. 1985;79:43-47. (Pubitemid 16179947)
64. Aubier M, Neukirch C, Maachi M, et al. Effect of slow-release theophylline on nasal antigen challenge in subjects with allergic rhinitis. Eur Respir J. 1998;11:1105-1110. (Pubitemid 28281030)
65. Nielson CP, Vestal RE, Sturm RJ, et al. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol. 1990;86:801-808.
66. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA. 2002;99:8921-8922.
67. Sydbom A, Fredholm BB. On the mechanism by which theophylline inhibits histamine release from rat mast cells. Acta Physiol Scand. 1982; 114:243-251. (Pubitemid 12185722)
68. Min YG, Ohyama M, Lee KS, et al. Effects of free radicals on ciliary movement in the human nasal epithelial cells. Auris Nasus Larynx. 1999; 26:159-163. (Pubitemid 29156269)
69. Lim S, Tomita K, Caramori G, et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med. 2001;164:273-276. (Pubitemid 34001294)
70. Calhoun WJ, Stevens CA, Lambert SB. Modulation of superoxide production of alveolar macrophages and peripheral blood mononuclear cells by beta-agonists and theophylline. J Lab Clin Med. 1991;117:514-522.
71. Jeurgens UR, Overlack A, Vetter H. Theophylline inhibits the formation of leukotriene B4 (LTB4) by enhancement of cyclic-AMP and prostaglandin E2 (PGE2) production in normal monocytes in vitro. Eur Respir J. 1993;17S:3685.
72. Sansone GR, Matin A, Wang SF, et al. Theophylline inhibits the production of nitric oxide by peripheral blood mononuclear cells from patients with asthma. Ann Allergy Asthma Immunol. 1998;81:90-95. (Pubitemid 28346131)
73. Hermens WA, Merkus FW. The influence of drugs on nasal ciliary movement. Pharm Res. 1987;4:445-449. (Pubitemid 18035238)
74. Costello JF, Piper PJ, eds. Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease. London, United kingdom: Parthenon; 1994.
75. Tamaoki J, Kondo M, Takizawa T. Effect of cAMP on ciliary function in rabbit tracheal epithelial cells. J Appl Physiol. 1989;66:1035-1039. (Pubitemid 19091325)
76. D'Alonzo GE. Theophylline revisited. Allergy Asthma Proc. 1996;17: 335-339. (Pubitemid 27034809)
77. Henkin RI. Growth factors in olfaction. In: Preedy VR, ed. The Handbook of Growth and Growth Monitoring in Health and Disease. Vol II. New York: Springer-Verlag, 2011:1417-1436.
78. Christen M, Kulasekara HD, Christen B, et al. Asymmetrical distribution of the second messenger c-di-GMP upon bacterial cell division. Science. 2010;328:1295-1297.